177A Stock Overview
Manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Kohjin Bio Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥1,745.00 |
52 Week High | JP¥3,065.00 |
52 Week Low | JP¥1,281.00 |
Beta | 0 |
11 Month Change | -3.06% |
3 Month Change | -2.84% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -26.37% |
Recent News & Updates
Recent updates
Shareholder Returns
177A | JP Biotechs | JP Market | |
---|---|---|---|
7D | -6.1% | -5.5% | -0.4% |
1Y | n/a | 15.4% | 11.4% |
Return vs Industry: Insufficient data to determine how 177A performed against the JP Biotechs industry.
Return vs Market: Insufficient data to determine how 177A performed against the JP Market.
Price Volatility
177A volatility | |
---|---|
177A Average Weekly Movement | 4.8% |
Biotechs Industry Average Movement | 8.3% |
Market Average Movement | 3.8% |
10% most volatile stocks in JP Market | 7.6% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 177A has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 177A's weekly volatility has decreased from 11% to 5% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1981 | 159 | Takahito Nakamura | www.kohjin-bio.jp |
Kohjin Bio Co., Ltd. manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for virus and recombinant protein production, hybridoma, human lymphocyte culture, and insect cell lines; gas permeable cell culture bags and other materials; cryopreservation agent of cells; medium supplements; normal human cells; normal human cell mediums; ES cell mediums; in-vitro fertilization and early embryo culture kits; and other culture and related products, such as supplements, cell separation solutions, physiological salt solutions, and research reagents. The company also offers clinical microbiology culture mediums for gram positive cocci, gram negative bacteria, and susceptibility testing; general differential, anaerobic growth, and fungal mediums; tube mediums for confirmation and expansion; microbiology culture mediums for food, such as mediums for sterilization test, E. coli and coliform bacteria, staphylococcus spp., bacillus cereus, and vibrio parahaemolyticus; culture mediums for determining total viable cell count; and campylobacter and fungal mediums.
Kohjin Bio Co., Ltd. Fundamentals Summary
177A fundamental statistics | |
---|---|
Market cap | JP¥8.92b |
Earnings (TTM) | JP¥384.00m |
Revenue (TTM) | JP¥4.77b |
23.2x
P/E Ratio1.9x
P/S RatioIs 177A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
177A income statement (TTM) | |
---|---|
Revenue | JP¥4.77b |
Cost of Revenue | JP¥2.89b |
Gross Profit | JP¥1.88b |
Other Expenses | JP¥1.50b |
Earnings | JP¥384.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 75.12 |
Gross Margin | 39.43% |
Net Profit Margin | 8.05% |
Debt/Equity Ratio | 65.1% |
How did 177A perform over the long term?
See historical performance and comparison